Puma Biotechnology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Puma Biotechnology sits in the top decile of US sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count).
Puma Biotechnology: 28 sponsored US clinical trials, 2 recruiting.
Puma Biotechnology sponsors 28 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 24 completed. 2 of these trials are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 3 trials.
Top-decile sponsor footprint
Puma Biotechnology ranks in the top decile of sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
24 of 26 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
28 total, page 1 of 1
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
NCT03786107
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
NCT02400476
Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects
NCT02334501
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
NCT01953926
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
NCT01827267
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
NCT01808573
A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects
NCT01142063
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
NCT01111825
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
NCT00915018
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
NCT00878709
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
NCT00838539
Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin
NCT00860223
Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib
NCT00864487
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
NCT00777101
Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)
NCT00814060
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
NCT00741260
Study Evaluating The Tolerability Of Multiple Doses Of HKI-272
NCT00757809
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
NCT00708903
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
NCT00706030
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
NCT00445458
Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects
NCT00498745
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
NCT00398567
Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
NCT00300781
Study Evaluating HKI-272 Administered to Healthy Subjects
NCT00366600
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
NCT00266877
Study Evaluating HKI-272 in Tumors
NCT00146172
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 9 |
| Phase 3 | 2 |
What is open in the Puma Biotechnology pipeline
2 recruiting of 28 indexed (7% open); 24 completed (86%).
Phase mix: 2 late (III/IV) vs 24 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (3 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Puma Biotechnology: open-pipeline peers nationwide
Peers matched on 28 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Puma Biotechnology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 28 trials (± recruiting share)
- Axsome Therapeutics · 28 trials · 21% recruiting
- Benaroya Research Institute · 28 trials · 14% recruiting
- CAMC Health System · 28 trials · 11% recruiting
- CTI BioPharma · 28 trials · 0% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Carol Fabian, MD · 7% recruiting · 14 trials
- Celldex Therapeutics · 7% recruiting · 42 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Mannkind Corporation · 7% recruiting · 42 trials
Related
What to do with this Puma Biotechnology page
28 registered trials is a research-attention snapshot, not an endorsement of Puma Biotechnology or any single study.
- 2 of Puma Biotechnology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Puma Biotechnology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Puma Biotechnology pipeline card: 28 registered trials from official public datasets.Report a data error.